Brian A Jonas
University of California, Davis · City of Hope Comprehensive Cancer Center LAO
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Brian A Jonas as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:00 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT04964505 · Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid LeukemiaBrian Jonas · terminated · Acute Myeloid Leukemia · principal investigator
- Ph2NCT04905810 · Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent FailureBrian Jonas · recruiting · Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia · principal investigator
- Ph1NCT03983824 · Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid LeukemiaNational Cancer Institute (NCI) · active not recruiting · Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia · principal investigator
- Ph2NCT03745352 · Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaNational Cancer Institute (NCI) · withdrawn · Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:00 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- NCI R50 Clinician Scientist AwardR50CA276013 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · fiscal years 2023 to 2026 · $87,347 awarded in 2026Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Integrated Cancer Biology ProgramP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Wolf-Dietrich Heyer · fiscal years 2009 to 2026Named on NCT04964505, NCT04905810
- Phase 1 and 2 Molecular and Clinical Pharmacodynamic Trials ETCTNUM1CA186717 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI A. Dimitrios Colevas, Alexey V. Danilov, PRIMO N. LARA, HEINZ JOSEF LENZ · fiscal years 2014 to 2026Named on NCT03983824, NCT03745352
Most cited trial papers
Clinical-trial papers with this author name in acute myeloid leukemia, ranked by citations from NIH iCite, fetched 2026-11-12 11:00 UTC. The ranking covers the 200 most relevant of 25 PubMed records, and a shared surname and initials can bring in a namesake. All 25 on PubMed
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.N Engl J Med · 20202,533 citationsRCR 110.4
- 633 citationsRCR 20.6
- 409 citationsRCR 14.2
- Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.Am J Hematol · 2024241 citationsRCR 32.1
- Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine.J Clin Oncol · 2022164 citationsRCR 12.0
- Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study.Am J Hematol · 2021138 citationsRCR 7.7
- Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.Lancet Haematol · 2023108 citationsRCR 8.5
- Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial.Blood · 202387 citationsRCR 7.6
- 81 citationsRCR 5.8
- 60 citationsRCR 3.0